<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362880</url>
  </required_header>
  <id_info>
    <org_study_id>FBB-FAD-2014</org_study_id>
    <nct_id>NCT02362880</nct_id>
  </id_info>
  <brief_title>Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study</brief_title>
  <official_title>Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease: 18F-Florbetaben Positron Emission Tomography Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Judit Pich Martínez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to assess safety of a single dose of FBB followed by PET
      scan in individuals at risk of genetic Alzheimer's disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse events of a single dose of FBB followed by PET scan in individuals at risk of genetic Alzheimer?s disease.</measure>
    <time_frame>At baseline, when FBB-PET is performed.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of FAD mutation carriers that present positive uptake after FBB-PET through visual examination</measure>
    <time_frame>At baseline, when FBB-PET is performed.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of FAD mutation carriers presenting standardized uptake value ratios (SUVRs) of FBB-PET higher than 1,4.</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areas of significant difference (p&lt;0,05) in regional SUVR between FAD mutation carriers and non-carriers.</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Earliest age of positive FBB-PET in FAD mutation carriers.</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual cortical areas with positive amyloid deposition at visual or semi-quantitative assessment</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>mutation carrier</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mutation non-carrier</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Florbetaben</intervention_name>
    <description>single dose of Florbetaben followed by PET scan</description>
    <arm_group_label>mutation carrier</arm_group_label>
    <arm_group_label>mutation non-carrier</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult children (&gt; 18 yo) of genetic Alzheimer?s disease patients with a known mutation
             in PSEN1, APP o PSEN2 genes and who are either cognitively normal (CDR=0) or have mild
             symptoms of cognitive decline (CDR 0.5 or 1)

          -  According to the principal investigator, participants must be committed to participate
             and complete all study procedures.

          -  Has signed the Informed Consent Form voluntarily to participate in the study

        Exclusion Criteria:

          -  Subjects that are not able to complete the study.

          -  Any major disease or history of a major disease, especially hepatobilliar disease (AST
             /ALT ? 5 x ULN) or advanced renal insufficiency (creatinine ? 2 x ULN)

          -  Current or previous history of alcohol abuse or epilepsy

          -  Allergic to Florbetaben or any of its constituents

          -  Multiple drug allergies and/or previous history of contrast allergy.

          -  Pregnancy or breast feeding or planned pregnancy during the study period

          -  Any disease or history of disease which, in the opinion of the investigator, can cause
             disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed
             thyroid function)

          -  Evidence for any other neurological or psychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raquel Sánchez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raquel Sánchez</last_name>
    <phone>+34932275400</phone>
    <phone_ext>5785</phone_ext>
    <email>RSANCHEZ@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Sánchez, MD</last_name>
      <phone>932275400</phone>
      <phone_ext>5785</phone_ext>
      <email>RSANCHEZ@clinic.ub.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2015</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Judit Pich Martínez</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

